File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Annexin A3 is a therapeutic target for CD133+ liver cancer stem cells

TitleAnnexin A3 is a therapeutic target for CD133+ liver cancer stem cells
Authors
KeywordsMedical sciences
Oncology
Issue Date2014
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/
Citation
The 105th Annual Meeting of the American Association for Cancer Research (AACR 2014), San Diego, CA., 5-9 April 2014. In Cancer Research, 2014, v. 74 n. 19 suppl., abstract no. 221 How to Cite?
AbstractFrequent tumor relapse in hepatocellular carcinoma (HCC) has been commonly attributed to the failure to completely eradicate cancer stem cells (CSCs) in the tumor residues by conventional treatments. We have previously reported that the tumor growth of HCC is fuelled, at least in part, by a small subset of CSCs marked by the CD133 surface phenotype. Our present study aims 1) to delineate the molecular mechanism by which CD133+ liver CSCs mediate HCC tumor formation and progression; and 2) to develop a novel diagnostic / prognostic biomarker and targeted therapy for HCC detection and treatment. RNA-Seq profiling was employed to compare the gene expression profiles between sorted CD133+ and CD133- subsets isolated from HCC cell lines ...
DescriptionThis journal suppl. entitled: Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA
Persistent Identifierhttp://hdl.handle.net/10722/214785
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorTong, M-
dc.contributor.authorFung, CM-
dc.contributor.authorGuan, XY-
dc.contributor.authorMa, S-
dc.date.accessioned2015-08-21T11:55:40Z-
dc.date.available2015-08-21T11:55:40Z-
dc.date.issued2014-
dc.identifier.citationThe 105th Annual Meeting of the American Association for Cancer Research (AACR 2014), San Diego, CA., 5-9 April 2014. In Cancer Research, 2014, v. 74 n. 19 suppl., abstract no. 221-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/214785-
dc.descriptionThis journal suppl. entitled: Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA-
dc.description.abstractFrequent tumor relapse in hepatocellular carcinoma (HCC) has been commonly attributed to the failure to completely eradicate cancer stem cells (CSCs) in the tumor residues by conventional treatments. We have previously reported that the tumor growth of HCC is fuelled, at least in part, by a small subset of CSCs marked by the CD133 surface phenotype. Our present study aims 1) to delineate the molecular mechanism by which CD133+ liver CSCs mediate HCC tumor formation and progression; and 2) to develop a novel diagnostic / prognostic biomarker and targeted therapy for HCC detection and treatment. RNA-Seq profiling was employed to compare the gene expression profiles between sorted CD133+ and CD133- subsets isolated from HCC cell lines ...-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/-
dc.relation.ispartofCancer Research-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectMedical sciences-
dc.subjectOncology-
dc.titleAnnexin A3 is a therapeutic target for CD133+ liver cancer stem cells-
dc.typeConference_Paper-
dc.identifier.emailTong, M: caroltm@hku.hk-
dc.identifier.emailGuan, XY: xyguan@hkucc.hku.hk-
dc.identifier.emailMa, S: stefma@hku.hk-
dc.identifier.authorityGuan, XY=rp00454-
dc.identifier.authorityMa, S=rp00506-
dc.description.naturepostprint-
dc.identifier.hkuros248959-
dc.identifier.volume74-
dc.identifier.issue19 suppl.-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats